niacinamide has been researched along with Glioma in 30 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 9.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "Pharmacological inhibition of the NAD salvage biosynthesis pathway using a highly specific inhibitor, KPT-9274, resulted in the reduction of NAD levels and related downstream metabolites, inhibited proliferation, and induced apoptosis in vitro in cell lines and ex vivo in human glioma tissue." | 8.12 | Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. ( Easley, M; Elder, JB; Lang, FF; Lapalombella, R; Lonser, R; Puduvalli, VK; Sampath, D; Sharma, P; Williams, K; Xu, J, 2022) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 7.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| " This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines." | 7.78 | Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012) |
| "Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems." | 6.76 | Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011) |
| " In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)." | 5.29 | Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995) |
| " Multiple glioma cell lines were analyzed for viability after treatment with radiation, temozolomide, or sorafenib or combinations of them." | 5.17 | A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. ( Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M, 2013) |
| "Pharmacological inhibition of the NAD salvage biosynthesis pathway using a highly specific inhibitor, KPT-9274, resulted in the reduction of NAD levels and related downstream metabolites, inhibited proliferation, and induced apoptosis in vitro in cell lines and ex vivo in human glioma tissue." | 4.12 | Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. ( Easley, M; Elder, JB; Lang, FF; Lapalombella, R; Lonser, R; Puduvalli, VK; Sampath, D; Sharma, P; Williams, K; Xu, J, 2022) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 3.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| " This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines." | 3.78 | Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. ( Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR, 2012) |
| " This study investigated the influence of P-gp and BCRP on the central nervous system (CNS) penetration of sorafenib, a multitargeted tyrosine kinase inhibitor currently being evaluated in clinical trials for glioma." | 3.77 | The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. ( Agarwal, S; Elmquist, WF; Ohlfest, JR; Sane, R, 2011) |
| " Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment." | 3.77 | Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. ( Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X, 2011) |
| "NG108-15 neuroblastoma x glioma somatic hybrid cells were permeabilized in the presence of [32P]NAD+ and then cultured for 18 h." | 3.68 | Gs alpha is a substrate for mono(ADP-ribosyl)transferase of NG108-15 cells. ADP-ribosylation regulates Gs alpha activity and abundance. ( Boyd, RS; Donnelly, LE; MacDermot, J, 1992) |
| "Sorafenib is an inhibitor of multiple kinases that has demonstrated antiproliferative and antiangiogenic activity in a number of in vitro and in vivo model systems." | 2.76 | Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. ( Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X, 2011) |
| "Malignant primary brain tumors have hitherto been incurable." | 1.30 | Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors. ( Brun, A; Kjellén, E; Pero, RW; Persson, RB; Salford, LG, 1997) |
| " In experimental models carbogen breathing and nicotinamide have been shown to act against hypoxia by different mechanisms and both modalities were tested in 16 patients with supratentorial malignant gliomas in combination with a conventional radiotherapy scheme (50 Gy in 25 daily fractions)." | 1.29 | Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. ( de Koster, A; Grotenhuis, JA; Kaanders, JH; Keyser, A; Prick, MJ; Thijssen, HO; van der Kogel, AJ; van der Maazen, RW; Wesseling, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.33) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 16 (53.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, J | 1 |
| Baxter, ME | 1 |
| Miller, HA | 1 |
| Chen, J | 1 |
| Williams, BJ | 1 |
| Frieboes, HB | 1 |
| Sharma, P | 1 |
| Xu, J | 1 |
| Williams, K | 1 |
| Easley, M | 1 |
| Elder, JB | 1 |
| Lonser, R | 1 |
| Lang, FF | 1 |
| Lapalombella, R | 1 |
| Sampath, D | 1 |
| Puduvalli, VK | 1 |
| Jakubowicz-Gil, J | 1 |
| Langner, E | 1 |
| Bądziul, D | 1 |
| Wertel, I | 1 |
| Rzeski, W | 1 |
| Hassler, MR | 1 |
| Ackerl, M | 1 |
| Flechl, B | 1 |
| Sax, C | 1 |
| Wöhrer, A | 1 |
| Widhalm, G | 1 |
| Dieckmann, K | 1 |
| Hainfellner, J | 1 |
| Preusser, M | 1 |
| Marosi, C | 1 |
| Bambury, RM | 1 |
| Morris, PG | 1 |
| Greenall, SA | 1 |
| Donoghue, JF | 1 |
| Van Sinderen, M | 1 |
| Dubljevic, V | 1 |
| Budiman, S | 1 |
| Devlin, M | 1 |
| Street, I | 1 |
| Adams, TE | 1 |
| Johns, TG | 1 |
| Kiprianova, I | 1 |
| Remy, J | 1 |
| Milosch, N | 1 |
| Mohrenz, IV | 1 |
| Seifert, V | 1 |
| Aigner, A | 1 |
| Kögel, D | 1 |
| Salloum, R | 1 |
| Hummel, TR | 1 |
| Kumar, SS | 1 |
| Dorris, K | 1 |
| Li, S | 1 |
| Lin, T | 1 |
| Daryani, VM | 1 |
| Stewart, CF | 1 |
| Miles, L | 1 |
| Poussaint, TY | 1 |
| Stevenson, C | 1 |
| Goldman, S | 1 |
| Dhall, G | 1 |
| Packer, R | 1 |
| Fisher, P | 1 |
| Pollack, IF | 2 |
| Fouladi, M | 1 |
| Boyett, J | 1 |
| Drissi, R | 1 |
| Sehm, T | 1 |
| Rauh, M | 1 |
| Wiendieck, K | 1 |
| Buchfelder, M | 1 |
| Eyüpoglu, IY | 1 |
| Savaskan, NE | 1 |
| Siegelin, MD | 1 |
| Raskett, CM | 1 |
| Gilbert, CA | 1 |
| Ross, AH | 2 |
| Altieri, DC | 1 |
| Yamada, K | 1 |
| Miyazaki, T | 1 |
| Hara, N | 1 |
| Tsuchiya, M | 1 |
| Sheng, Z | 2 |
| Li, L | 1 |
| Zhu, LJ | 1 |
| Smith, TW | 1 |
| Demers, A | 1 |
| Moser, RP | 1 |
| Green, MR | 2 |
| Lemasson, B | 2 |
| Serduc, R | 1 |
| Maisin, C | 1 |
| Bouchet, A | 1 |
| Coquery, N | 1 |
| Robert, P | 1 |
| Le Duc, G | 1 |
| Troprès, I | 1 |
| Rémy, C | 2 |
| Barbier, EL | 2 |
| Agarwal, S | 1 |
| Sane, R | 1 |
| Ohlfest, JR | 1 |
| Elmquist, WF | 1 |
| Christen, T | 1 |
| Tizon, X | 1 |
| Farion, R | 1 |
| Fondraz, N | 1 |
| Provent, P | 1 |
| Segebarth, C | 1 |
| Genne, P | 1 |
| Duchamp, O | 1 |
| Nabors, LB | 1 |
| Supko, JG | 1 |
| Rosenfeld, M | 1 |
| Chamberlain, M | 1 |
| Phuphanich, S | 1 |
| Batchelor, T | 1 |
| Desideri, S | 1 |
| Ye, X | 1 |
| Wright, J | 1 |
| Gujar, S | 1 |
| Grossman, SA | 1 |
| Du, W | 1 |
| Zhou, JR | 1 |
| Wang, DL | 1 |
| Gong, K | 1 |
| Zhang, QJ | 1 |
| Den, RB | 1 |
| Kamrava, M | 1 |
| Werner-Wasik, M | 1 |
| Dougherty, E | 1 |
| Marinucchi, M | 1 |
| Lawrence, YR | 1 |
| Hegarty, S | 1 |
| Hyslop, T | 1 |
| Andrews, DW | 1 |
| Glass, J | 1 |
| Friedman, DP | 1 |
| Camphausen, K | 1 |
| Dicker, AP | 1 |
| Jane, EP | 1 |
| Premkumar, DR | 1 |
| Wikstrand, CJ | 2 |
| Bigner, SH | 1 |
| Bigner, DD | 2 |
| Donnelly, LE | 2 |
| Boyd, RS | 2 |
| Williams, RJ | 1 |
| Kelly, E | 1 |
| MacDermot, J | 2 |
| van der Maazen, RW | 1 |
| Thijssen, HO | 1 |
| Kaanders, JH | 1 |
| de Koster, A | 1 |
| Keyser, A | 1 |
| Prick, MJ | 1 |
| Grotenhuis, JA | 1 |
| Wesseling, P | 1 |
| van der Kogel, AJ | 1 |
| Lambin, P | 1 |
| Poortmans, P | 1 |
| Menten, J | 1 |
| Hamers, HP | 1 |
| Salford, LG | 1 |
| Brun, A | 1 |
| Kjellén, E | 1 |
| Pero, RW | 1 |
| Persson, RB | 1 |
| Mahaley, MS | 1 |
| Kolbe, H | 1 |
| Keller, K | 1 |
| Lange, K | 1 |
| Herken, H | 1 |
| Roerig, SC | 1 |
| Loh, HH | 1 |
| Law, PY | 1 |
| Coper, H | 1 |
4 trials available for niacinamide and Glioma
| Article | Year |
|---|---|
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Alanine Transaminase; Antineoplastic Agents; Blood Cell Count; Central Nervous System Ne | 2016 |
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progress | 2011 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell | 2013 |
[Studies of the NAD(P) glycohydrolase activity in human brain tumors].
Topics: Adenoma, Chromophobe; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Enzyme Induction; Epen | 1967 |
26 other studies available for niacinamide and Glioma
| Article | Year |
|---|---|
Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
Topics: Adenosine; Glioma; Humans; NAD; Niacinamide | 2022 |
Metabolomic differentiation of tumor core versus edge in glioma.
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioma; Humans; M | 2023 |
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Topics: Animals; Cell Line, Tumor; Cytokines; Glioma; Humans; Mice; NAD; Niacinamide; Nicotinamide Phosphori | 2022 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio | 2014 |
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neop | 2014 |
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Ni | 2014 |
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Topics: Analgesics; Animals; Antibodies, Monoclonal; Apoptosis; Brain Neoplasms; Cell Line, Tumor; ErbB Rece | 2015 |
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Topics: Activating Transcription Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; A | 2016 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, | 2010 |
Interferon-gamma elevates nicotinamide N-methyltransferase activity and nicotinamide level in human glioma cells.
Topics: Antineoplastic Agents; Cell Survival; Enzyme Activation; Glioma; Humans; Interferon-gamma; Niacinami | 2010 |
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP | 2010 |
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neopl | 2010 |
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line | 2011 |
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Respo | 2012 |
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blottin | 2006 |
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
Topics: 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; 2',3'-Cyclic-Nucleotide Phosphodiesterases; Antibodies | 1983 |
Inhibition of ADP-ribosyltransferase increases synthesis of Gs alpha in neuroblastoma x glioma hybrid cells and reverses iloprost-dependent heterologous loss of fluoride-sensitive adenylate cyclase.
Topics: Adenylyl Cyclase Inhibitors; ADP Ribose Transferases; Blood Platelets; Fluorides; Glioma; GTP-Bindin | 1995 |
Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas.
Topics: Administration, Inhalation; Aged; Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Female | 1995 |
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
Topics: Brain Neoplasms; Carbon Dioxide; Combined Modality Therapy; Glioma; Humans; Niacinamide; Oxygen; Rad | 1997 |
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Topics: Animals; Astrocytoma; Brain Neoplasms; Cell Division; Combined Modality Therapy; DNA Repair; Enzyme | 1997 |
Surface antigenic characteristics of human glial brain tumor cells.
Topics: Antibodies, Neoplasm; Antibody Specificity; Antigens, Neoplasm; Brain Neoplasms; Cell Line; Cell Mem | 1977 |
Metabolic consequences of drug-induced inhibition of the pentose phosphate pathway in neuroblastoma and glioma cells.
Topics: 6-Aminonicotinamide; Animals; Brain; Cell Line; Glioma; Gluconates; Glucose; Glucosephosphates; Lact | 1976 |
Gs alpha is a substrate for mono(ADP-ribosyl)transferase of NG108-15 cells. ADP-ribosylation regulates Gs alpha activity and abundance.
Topics: Adenosine Diphosphate Ribose; ADP Ribose Transferases; Blotting, Western; Cholera Toxin; Glioma; GTP | 1992 |
Requirement of ADP-ribosylation for the pertussis toxin-induced alteration in electrophoretic mobility of G-proteins.
Topics: Adenosine Diphosphate Ribose; Animals; Autoradiography; Cell Line; Electrophoresis, Polyacrylamide G | 1991 |